[A23-12] Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114
Last updated 06.04.2023
Project no.:
A23-12
Commission:
Commission awarded on 21.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy
Result of dossier assessment:
Unchanged after addendum: hint of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-114 | Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.